Pantoprazole , 10mMinDMSO , 102625-70-7

CAS NO.：102625-70-7

Empirical Formula: C16H15F2N3O4S

Molecular Weight: 383.37

MDL number: MFCD00870182

EINECS: 600-331-6

PRODUCT Properties

• Melting point: 139-140° (dec)
• Boiling point: 586.9±60.0 °C(Predicted)
• Density: 1.51±0.1 g/cm3(Predicted)
• storage temp.: Inert atmosphere,Store in freezer, under -20°C
• solubility: Chloroform (Slightly), Methanol (Slightly, Heated, Sonicated)
• form: Solid
• pka: pKa1 3.92; pKa2 8.19(at 25℃)
• color: Off-White to Pale Orange
• BCS Class: 3
• InChI: InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
• InChIKey: IQPSEEYGBUAQFF-UHFFFAOYSA-N
• SMILES: C1(S(CC2=NC=CC(OC)=C2OC)=O)NC2=CC(OC(F)F)=CC=C2N=1

Description and Uses

Pantoprazole, an irreversible proton pump inhibitor, reached its first market worldwide in Germany for acute treatment of gastric and duodenal ulcers and gastroesophageal reflux disease. Proton pump inhibitors are more effective than other strategies in inhibiting acid secretion since they function at the final step of acid production, therefore, provide superior symptom relief and healing in all acid related diseases. As the third substituted benzimidazole proton pump inhibitor marketed, pantoprazole not only has superior ulcer-preventing effect but also is more potent than omeprazole in healing acetic acid-induced gastric and duodenal ulcers with extremely low acute toxicity. The mechanism of action for this class of compounds has been suggested to be mediated via the protonated form of the molecule which selectively reacts with cysteines present on the extracytoplasmic face of the enzyme to form covalent disulfide bonds.

proton pump inhibitor, gastric acid release inhibitor, antiulcer

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302+H312+H332
• Hazard Codes: Xn
• Risk Statements: 20/21/22-37/38-41-48
• Safety Statements: 22-26-36/37/39-45